keyword
MENU ▼
Read by QxMD icon Read
search

major depressive disorder biomarkers

keyword
https://www.readbyqxmd.com/read/28541649/consensus-recommendations-for-the-clinical-application-of-repetitive-transcranial-magnetic-stimulation-rtms-in-the-treatment-of-depression
#1
Shawn M McClintock, Irving M Reti, Linda L Carpenter, William M McDonald, Marc Dubin, Stephan F Taylor, Ian A Cook, John O'Reardon, Mustafa M Husain, Christopher Wall, Andrew D Krystal, Shirlene M Sampson, Oscar Morales, Brent G Nelson, Vassilios Latoussakis, Mark S George, Sarah H Lisanby
OBJECTIVE: To provide expert recommendations for the safe and effective application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of major depressive disorder (MDD). PARTICIPANTS: Participants included a group of 17 expert clinicians and researchers with expertise in the clinical application of rTMS, representing both the National Network of Depression Centers (NNDC) rTMS Task Group and the American Psychiatric Association Council on Research (APA CoR) Task Force on Novel Biomarkers and Treatments...
May 23, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28539304/emindlog-self-measurement-of-anxiety-and-depression-using-mobile-technology
#2
Thomas M Penders, Karl L Wuensch, Philip T Ninan
BACKGROUND: Quantifying anxiety and depressive experiences permits individuals to calibrate where they are and monitor intervention-associated changes. eMindLog is a novel self-report measure for anxiety and depression that is grounded in psychology with an organizing structure based on neuroscience. OBJECTIVE: Our aim was to explore the psychometric properties of eMindLog in a nonclinical sample of subjects. METHODS: In a cross-sectional study of eMindLog, a convenience sample of 198 adults provided informed consent and completed eMindLog and the Hospital Anxiety and Depression Scale (HADS) as a reference...
May 24, 2017: JMIR Research Protocols
https://www.readbyqxmd.com/read/28530238/micrornas-146a-b-5-and-425-3p-and-24-3p-are-markers-of-antidepressant-response-and-regulate-mapk-wnt-system-genes
#3
Juan Pablo Lopez, Laura M Fiori, Cristiana Cruceanu, Rixing Lin, Benoit Labonte, Hannah M Cates, Elizabeth A Heller, Vincent Vialou, Stacy M Ku, Christophe Gerald, Ming-Hu Han, Jane Foster, Benicio N Frey, Claudio N Soares, Daniel J Müller, Faranak Farzan, Francesco Leri, Glenda M MacQueen, Harriet Feilotter, Kathrin Tyryshkin, Kenneth R Evans, Peter Giacobbe, Pierre Blier, Raymond W Lam, Roumen Milev, Sagar V Parikh, Susan Rotzinger, Steven C Strother, Cathryn M Lewis, Katherine J Aitchison, Gayle M Wittenberg, Naguib Mechawar, Eric J Nestler, Rudolf Uher, Sidney H Kennedy, Gustavo Turecki
Antidepressants (ADs) are the most common treatment for major depressive disorder (MDD). However, only ∼30% of patients experience adequate response after a single AD trial, and this variability remains poorly understood. Here, we investigated microRNAs (miRNAs) as biomarkers of AD response using small RNA-sequencing in paired samples from MDD patients enrolled in a large, randomized placebo-controlled trial of duloxetine collected before and 8 weeks after treatment. Our results revealed differential expression of miR-146a-5p, miR-146b-5p, miR-425-3p and miR-24-3p according to treatment response...
May 22, 2017: Nature Communications
https://www.readbyqxmd.com/read/28529691/recent-advances-in-predicting-responses-to-antidepressant-treatment
#4
REVIEW
Thomas Frodl
Major depressive disorder is one of the leading causes of disability in the world since depression is highly frequent and causes a strong burden. In order to reduce the duration of depressive episodes, clinicians would need to choose the most effective therapy for each individual right away. A prerequisite for this would be to have biomarkers at hand that would predict which individual would benefit from which kind of therapy (for example, pharmacotherapy or psychotherapy) or even from which kind of antidepressant class...
2017: F1000Research
https://www.readbyqxmd.com/read/28529365/long-noncoding-rnas-new-evidence-for-overlapped-pathogenesis-between-major-depressive-disorder-and-generalized-anxiety-disorder
#5
Xuelian Cui, Wei Niu, Lingming Kong, Mingjun He, Kunhong Jiang, Shengdong Chen, Aifang Zhong, Wanshuai Li, Jim Lu, Liyi Zhang
BACKGROUND: About half of patients with major depressive disorder (MDD) have clinically meaningful levels of anxiety. Greater severity of depressive illness and functional impairment has been reported in patients with high levels of anxiety accompanying depression. The pathogenesis for the comorbidity was still unsure. AIM: This study aimed to determine whether there would be molecular link for overlapped pathogenesis between MDD and anxiety disorder. MATERIALS AND METHODS: Using long noncoding RNA (lncRNA) microarray profiling and reverse transcription polymerase chain reaction, six downregulated lncRNAs and three upregulated lncRNAs had been identified to be the potential biomarkers for MDD and generalized anxiety disorder (GAD), respectively...
January 2017: Indian Journal of Psychiatry
https://www.readbyqxmd.com/read/28520926/investigation-of-mir-1202-mir-135a-and-mir-16-in-major-depressive-disorder-and-antidepressant-response
#6
Laura M Fiori, Juan Pablo Lopez, Stephane Richard-Devantoy, Marcelo Berlim, Eduardo Chachamovich, Fabrice Jollant, Jane Foster, Susan Rotzinger, Sidney Kennedy, Gustavo Turecki
Background: Major depressive disorder is a debilitating illness, which is most commonly treated with antidepressant drugs. As the majority of patients do not respond on their first trial, there is great interest in identifying biological factors which indicate the most appropriate treatment for each patient. Studies suggest that microRNA represent excellent biomarkers to predict antidepressant response. Methods: We investigated the expression of miR-1202, miR-135a, and miR-16 in peripheral blood from two cohorts of depressed patients who received eight weeks of antidepressant therapy...
May 16, 2017: International Journal of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28503402/physical-exercise-for-treatment-of-mood-disorders-a-critical-review
#7
C M Hearing, W C Chang, K L Szuhany, T Deckersbach, A A Nierenberg, L G Sylvia
PURPOSE OF THE REVIEW: The purpose of this review is to critically assess the evidence for exercise as an adjunct intervention for major depressive disorder and bipolar disorder, chronic conditions characterized by frequent comorbid conditions as well as interepisodic symptoms with poor quality of life and impaired functioning. Individuals with these mood disorders are at higher risk of cardiovascular disease and premature death in part because of increased rates of obesity, inactivity, and diabetes mellitus compared to the general population...
December 2016: Current Behavioral Neuroscience Reports
https://www.readbyqxmd.com/read/28465217/antidepressants-induce-autophagy-dependent-nlrp3-inflammasome-inhibition-in-major-depressive-disorder
#8
Elísabet Alcocer-Gómez, Nieves Casas-Barquero, Matthew R Williams, Samuel L Romero-Guillena, Diego Cañadas-Lozano, Pedro Bullón, José Antonio Sánchez-Alcazar, José M Navarro-Pando, Mario D Cordero
Major Depressive Disorder (MDD, ICD-10: F-33) is a prevalent illness in which the pathogenic mechanism remains elusive. Recently an important role has been attributed to neuro-inflammation, and specifically the NLRP3-inflammasome complex, in the pathogenesis of MDD. This suggests a key role for immunomodulation as a key pathway in the treatment of this disorder. This study evaluates the involvement of nine common antidepressants in the NLRP3-inflammasome complex (fluoxetine, paroxetine, mianserin, mirtazapine, venlafaxine, desvenlafaxine, amitriptyline, imipramine and agomelatine), both in in vitro THP-1 cells stimulated by ATP, and in a stress-induced depressive animal or MDD patients...
May 2, 2017: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/28458140/resting-state-brain-network-function-in-major-depression-depression-symptomatology-antidepressant-treatment-effects-future-research
#9
REVIEW
Janis Brakowski, Simona Spinelli, Nadja Dörig, Oliver Gero Bosch, Andrei Manoliu, Martin Grosse Holtforth, Erich Seifritz
The alterations of functional connectivity brain networks in major depressive disorder (MDD) have been subject of a large number of studies. Using different methodologies and focusing on diverse aspects of the disease, research shows heterogeneous results lacking integration. Disrupted network connectivity has been found in core MDD networks like the default mode network (DMN), the central executive network (CEN), and the salience network, but also in cerebellar and thalamic circuitries. Here we review literature published on resting state brain network function in MDD focusing on methodology, and clinical characteristics including symptomatology and antidepressant treatment related findings...
April 24, 2017: Journal of Psychiatric Research
https://www.readbyqxmd.com/read/28457485/motor-activity-markers-of-circadian-timekeeping-are-related-to-ketamine-s-rapid-antidepressant-properties
#10
Wallace C Duncan, Elizabeth Slonena, Nadia S Hejazi, Nancy Brutsche, Kevin C Yu, Lawrence Park, Elizabeth D Ballard, Carlos A Zarate
BACKGROUND: The rapid clinical antidepressant effects of the glutamatergic modulator ketamine may be due to its ability to restore synaptic plasticity and related effects on sleep-wake and circadian systems. Preclinical studies indicate that ketamine alters expression of circadian clock-associated molecules, and clinical studies of ketamine on plasticity-related biomarkers further suggest an association with sleep slow waves and sleep homeostasis. METHODS: Wrist-activity monitors were used to examine the pharmacologic and rapid antidepressant effects of ketamine on markers of circadian timekeeping (amplitude and timing) in mood disorders...
March 28, 2017: Biological Psychiatry
https://www.readbyqxmd.com/read/28449564/dehydroepiandrosterone-sulfate-level-varies-nonlinearly-with-symptom-severity-in-major-depressive-disorder
#11
Dasom Uh, Hyun-Ghang Jeong, Kwang-Yeon Choi, So-Young Oh, Suji Lee, Seung-Hyun Kim, Sook-Haeng Joe
Objective: The pathophysiology of major depressive disorder (MDD) is still not well understood. Conflicting results for surrogate. biomarkers in MDD have been reported, which might be a consequence of the heterogeneity of MDD patients. Therefore, we aim to investigate how the severity of depression and various symptom domains are related to the levels of dehydroepiandrosterone sulfate (DHEA-s) in MDD patients. Methods: We recruited 117 subjects from a general practice...
May 31, 2017: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28441923/lowered-pon1-activities-are-strongly-associated-with-depression-and-bipolar-disorder-recurrence-of-hypo-mania-and-depression-increased-disability-and-lowered-quality-of-life
#12
Estefania Gastaldello Moreira, Dalmo Guilherme Correia, Kamila Landucci Bonifácio, Juliana Brum de Moraes, Fernanda Liboni Cavicchioli, Carolina Sampaio Nunes, Sandra Odebrecht Vargas Nunes, Heber Odebrecht Vargas, Décio Sabbatini Barbosa, Michael Maes
BACKGROUND: Mood disorders (MD) frequently co-exist with cardiovascular disease (CVD) and immune-inflammatory and oxidative stress are important shared pathophysiological pathways. Even though there is an extensive investigation of the enzyme paraoxonase 1 (PON1) as a biomarker of susceptibility for CVD, there are only few reports studying PON1 in MD. OBJECTIVES: To determine the association between PON1 activities as well as functional genotypes and MD diagnosis, clinical characteristics and outcomes...
April 26, 2017: World Journal of Biological Psychiatry
https://www.readbyqxmd.com/read/28441588/reduced-ena78-levels-as-novel-biomarker-for-major-depressive-disorder-and-venlafaxine-efficiency-result-from-a-prospective-longitudinal-study
#13
Zezhi Li, Zuowei Wang, Chen Zhang, Jun Chen, Yousong Su, Jia Huang, Zhenghui Yi, Chengmei Yuan, Wu Hong, Yong Wang, Zhiguo Wu, Yingyan Hu, Lan Cao, Daihui Peng, Yangtai Guan, Yimin Zou, Shunying Yu, Donghong Cui, Yiru Fang
Although lines of evidence demonstrated that cytokines play an important role in the pathogenesis of major depressive disorder (MDD), none of the them have been established as reliable biomarkers. We use our previous whole-genome cRNA microarray data to identify epithelial cell-derived neutrophil-activating peptide 78 (ENA78), the most differentially expressed cytokine in peripheral blood between MDD patients and healthy controls; and then we confirmed the result by the quantitative reverse transcription-polymerase chain reaction (RT-qPCR) and enzyme-linked immunosorbent assay (ELISA) for mRNA and protein level, respectively, in an independent drug-naïve first-episode sample set...
March 18, 2017: Psychoneuroendocrinology
https://www.readbyqxmd.com/read/28439746/plasma-phosphatidylethanolamine-and-triacylglycerol-fatty-acid-concentrations-are-altered-in-major-depressive-disorder-patients-with-seasonal-pattern
#14
Yurika Otoki, Marie Hennebelle, Anthony J Levitt, Kiyotaka Nakagawa, Walter Swardfager, Ameer Y Taha
Disturbances in peripheral and brain lipid metabolism, including the omega-3 fatty acid docosahexaenoic acid (DHA), have been reported in major depressive disorder (MDD). However, these changes have yet to be confirmed in MDD with seasonal pattern (MDD-s), a subtype of recurrent MDD. The present exploratory study quantified plasma plasmalogen and diacyl-phospholipid species, and fatty acids within total phospholipids, cholesteryl esters, triacylglycerols and free fatty acids in non-medicated MDD-s participants (n = 9) during euthymia in summer or fall, and during depression in winter in order to screen for potential high sensitivity lipid biomarkers...
April 24, 2017: Lipids
https://www.readbyqxmd.com/read/28438543/modulation-of-motor-cortex-excitability-predicts-antidepressant-response-to-prefrontal-cortex-repetitive-transcranial-magnetic-stimulation
#15
Albino J Oliveira-Maia, Daniel Press, Alvaro Pascual-Leone
BACKGROUND: Repetitive transcranial magnetic stimulation (rTMS) targeting the left dorsolateral prefrontal cortex (DLPFC) is a treatment option for patients with medication-resistant major depressive disorder (MDD). However, antidepressant response is variable and there are currently no response predictors with sufficient accuracy for clinical use. OBJECTIVE: We report on results of an observational open-label study to determine whether the modulatory effect of 10 Hz motor cortex (MC) rTMS is predictive of the antidepressant effect of 10 Hz DLPFC rTMS...
March 31, 2017: Brain Stimulation
https://www.readbyqxmd.com/read/28438472/shared-metabolic-and-immune-inflammatory-oxidative-and-nitrosative-stress-pathways-in-the-metabolic-syndrome-and-mood-disorders
#16
REVIEW
Luiz Gustavo Piccoli de Melo, Sandra Odebrecht Vargas Nunes, George Anderson, Heber Odebrecht Vargas, Décio Sabbattini Barbosa, Piotr Galecki, André F Carvalho, Michael Maes
This review examines the shared immune-inflammatory, oxidative and nitrosative stress (IO&NS) and metabolic pathways underpinning metabolic syndrome (MetS), bipolar disorder (BD) and major depressive disorder (MDD). Shared pathways in both MetS and mood disorders are low grade inflammation, including increased levels of pro-inflammatory cytokines and acute phase proteins, increased lipid peroxidation with formation of malondialdehyde and oxidized low density lipoprotein cholesterol (LDL-c), hypernitrosylation, lowered levels of antioxidants, most importantly zinc and paraoxonase (PON1), increased bacterial translocation (leaky gut), increased atherogenic index of plasma and Castelli risk indices; and reduced levels of high-density lipoprotein (HDL-c) cholesterol...
April 21, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28382573/serum-global-metabolomics-profiling-reveals-profound-metabolic-impairments-in-patients-with-mps-iiia-and-mps-iiib
#17
Haiyan Fu, Aaron S Meadows, Ricardo J Pineda, Robert P Mohney, Steve Stirdivant, Douglas M McCarty
The monogenic defects in specific lysosomal enzymes in mucopolysaccharidosis (MPS) III lead to lysosomal storage of glycosaminoglycans and complex CNS and somatic pathology, for which the detailed mechanisms remain unclear. In this study, serum samples from patients with MPS IIIA (age 2-9 yr) and MPS IIIB (2-13 yr) and healthy controls (age 2-9 yr) were assayed by global metabolomics profiling of 658 metabolites using mass spectrometry. Significant alterations were detected in 423 metabolites in all MPS III patients, of which 366 (86...
April 5, 2017: Metabolic Brain Disease
https://www.readbyqxmd.com/read/28375203/the-serum-protein-levels-of-the-tpa-bdnf-pathway-are-implicated-in-depression-and-antidepressant-treatment
#18
H Jiang, S Chen, C Li, N Lu, Y Yue, Y Yin, Y Zhang, X Zhi, D Zhang, Y Yuan
Evidence demonstrates that brain-derived neurotrophic factor (BDNF) has a pivotal role in the pathogenesis of major depressive disorder (MDD). Precursor-BDNF (proBDNF) and mature BDNF (mBDNF) have opposing biological effects in neuroplasticity, and the tissue-type plasminogen activator (tPA)/plasmin system is crucial in the cleavage processing of proBDNF to mBDNF. However, very little is known about the role of the tPA-BDNF pathway in MDD. We examined serum protein concentrations in the tPA-BDNF pathway, including tPA, BDNF, tropomyosin receptor kinase B (TrkB), proBDNF and p75NTR, obtained from 35 drug-free depressed patients before and after 8 weeks of escitalopram (mean 12...
April 4, 2017: Translational Psychiatry
https://www.readbyqxmd.com/read/28371072/can-lncrnas-be-indicators-for-the-diagnosis-of-early-onset-or-acute-schizophrenia-and-distinguish-major-depressive-disorder-and-generalized-anxiety-disorder-a-cross-validation-analysis
#19
Xuelian Cui, Wei Niu, Lingming Kong, Mingjun He, Kunhong Jiang, Shengdong Chen, Aifang Zhong, Wanshuai Li, Jim Lu, Liyi Zhang
Depression and anxiety are apparent symptoms in the early onset or acute phase of schizophrenia (SZ), which complicate timely diagnosis and treatment. It is imperative to seek an indicator to distinguish schizophrenia from depressive and anxiety disorders. Using lncRNA microarray profiling and RT-PCR, three up-regulated lncRNAs in SZ, six down-regulated lncRNAs in major depressive disorder (MDD), and three up-regulated lncRNAs in generalized anxiety disorder (GAD) had been identified as potential biomarkers...
March 28, 2017: American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics
https://www.readbyqxmd.com/read/28367128/the-role-of-norepinephrine-and-its-%C3%AE-adrenergic-receptors-in-the-pathophysiology-and-treatment-of-major-depressive-disorder-and-schizophrenia-a-systematic-review
#20
REVIEW
Vladimir Maletic, Anna Eramo, Keva Gwin, Steve J Offord, Ruth A Duffy
Norepinephrine (NE) is recognized as having a key role in the pathophysiology of major depressive disorder (MDD) and schizophrenia, although its distinct actions via α-adrenergic receptors (α-ARs) are not well defined. We performed a systematic review examining the roles of NE and α-ARs in MDD and schizophrenia. PubMed and ProQuest database searches were performed to identify English language papers published between 2008 and 2015. In total, 2,427 publications (PubMed, n = 669; ProQuest, n = 1,758) were identified...
2017: Frontiers in Psychiatry
keyword
keyword
106962
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"